MSCI
MSCI
$661.53
+0.71%
MSCI, Inc. operates as a global provider of critical decision-support tools and services for the investment community, with its largest and most profitable segment being its index franchise that benchmarks roughly $18 trillion in assets, including over $2.3 trillion in ETF assets linked to MSCI indexes, alongside analytics, ESG/climate, and private-asset reporting businesses. The company functions as a high-margin, subscription-like toll booth on global asset allocation, deriving recurring revenue from asset-based index fees and sticky multi-year software and data contracts that give it a distinct competitive moat versus traditional asset managers and exchanges. The current investor narrative centers on the durability of that recurring revenue model following a strong third-quarter 2026 print (revenue up 12.4% year over year with EPS beating estimates), which reignited enthusiasm after a mid-year drawdown tied to market volatility and concerns about asset-based fee sensitivity. Debate now hinges on whether accelerating ETF-linked flows, ESG data demand, and operating leverage can sustain premium multiples as the stock trades near the upper end of its 52-week range.…
MSCI
MSCI
$661.53
Related headlines
Investment Opinion: Should I buy MSCI Today?
Rating: Hold (accumulate on weakness). MSCI is a top-decile quality compounder — 12.42% Q3 2026 revenue growth, 82.94% gross margin, 56.29% operating margin, $1.54B trailing FCF — but at $641.01 the stock already discounts much of that excellence, with the $684.12 average analyst target (16 Buy, 1 Hold, 1 Sell; consensus 'strong_buy') implying only +6.7% upside after a 15.42% one-month rally. The core thesis is that MSCI's index franchise, a recurring toll on roughly $18 trillion of benchmarked assets including $2.3 trillion in linked ETF AUM, deserves a premium multiple, but not an unlimited one at 36.82x trailing PE.
The supporting evidence is genuinely strong: revenue grew 12.42% YoY to $892.0M with steady sequential cadence ($850.8M, $867.0M, $892.0M), net margin is 38.36%, EBITDA margin 62.15%, and Q3 FCF of $385.4M on just $50.7M capex funded $552.6M of buybacks plus $147.8M of dividends while repaying $335M of debt. Forward PE of 28.58x versus 36.82x trailing implies roughly 22% earnings growth, consistent with consensus 2027 EPS of $31.96 and revenue of $4.83B. Relative strength is idiosyncratic — +20.41 points versus SPY over one month while the S&P fell 4.99% — confirming fundamental momentum rather than beta.
The risks that could invalidate this view are valuation compression (PEG of 3.48, EV/EBITDA of 25.93x versus 10–14x for diversified financial-data peers), asset-based fee sensitivity (Index is ~60% of revenue at $532.6M, levered to global equity levels), and thin liquidity (current ratio 0.899, $261.0M cash, interest coverage ~6.7x). This Hold would upgrade to Buy if the stock pulls back toward the $585 analyst low (implying ~28x forward PE) or if ETF-linked flows accelerate enough to push 2027 EPS estimates above $33; it would downgrade to Sell if revenue growth decelerates below 10% or a market drawdown compresses the fee base. Verdict: fairly valued to modestly rich — a premium quality name trading near the upper end of its own historical band, not a bargain.
Sign up to view all
MSCI 12-Month Price Forecast
MSCI is a genuinely exceptional business — 12.42% growth, 82.94% gross margins, and $1.54B of trailing FCF — but the investment question at $641.01 is price, not quality. The 36.82x trailing PE and 3.48 PEG already embed years of compounding, and the +6.7% implied upside to the $684.12 average target is thin compensation for a stock with 1.192 beta and a demonstrated -18% drawdown. The base case (55% probability) sees the stock tracking toward $660–$690 as consensus 2027 EPS of $31.96 materializes and the forward PE of 28.58x holds. I would upgrade to bullish on a pullback toward the $585 analyst low (roughly 28x forward earnings) or on evidence that ETF-linked flows are accelerating 2027 EPS estimates above $33; I would downgrade to bearish if revenue growth slips below 10% or a market drawdown threatens the asset-based fee base.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on MSCI's 12-month outlook, with a consensus price target around $686.18 and implied upside of +3.7% versus the current price.
Average Target
$686.18
18 analysts
Implied Upside
+3.7%
vs. current price
Analyst Count
18
covering this stock
Price Range
$585 - $760
Analyst target range
Coverage is broad and overwhelmingly bullish: 17 analysts cover MSCI with 16 Buy ratings, 1 Hold, and 1 Sell, producing a consensus recommendation of "strong_buy" and a recommendation mean of 1.5. The average target price is $684.12, which implies roughly +6.7% upside from the current $641.01 — a modest but positive expected return that reflects how much of the good news is already in the price after the recent 15.4% one-month rally. Consensus 2027 EPS of $31.96 and revenue of $4.83 billion underpin that target, and the bullish tilt is reinforced by a steady stream of reiterations from Barclays, Wells Fargo, RBC, Morgan Stanley, JPMorgan, and Evercore ISI through October and early November 2026.
The target range runs from a low of $585.00 to a high of $735.00, a spread of about 26% of the current price that signals meaningful dispersion in assumptions. The high target of $735 implies roughly +14.7% upside and likely assumes continued double-digit revenue growth, sustained ETF-linked asset flows, and multiple expansion back toward the stock's historical premium band. The low target of $585 implies about -8.7% downside and likely prices in a market-driven slowdown in asset-based fees, margin pressure from heavier investment spending, or a de-rating toward peer multiples. Notably, the institutional ratings log shows only reiterations — no upgrades or downgrades — over the past several months, suggesting high conviction but also a lack of fresh catalysts; the wide spread combined with unanimous bullishness means the key risk is not analyst skepticism but the possibility that the consensus is crowded and vulnerable to any deceleration in flows or market levels.
Bulls vs Bears: MSCI Investment Factors
The bull case currently holds the stronger evidence: 12.42% revenue growth, 82.94% gross margins, $1.54B trailing FCF, and 16 of 17 Buy ratings are concrete and durable, and the stock's 20.41-point one-month outperformance versus SPY confirms real fundamental momentum rather than beta. The bear case rests less on business deterioration than on price — a 36.82x trailing PE, 25.93x EV/EBITDA, and PEG of 3.48 mean the market has already capitalized years of compounding, leaving only +6.7% implied upside to the average $684.12 target. The single most important tension is the sensitivity of asset-based index fees (~60% of revenue) to global market levels: if equity markets hold and ETF flows keep accelerating, the premium multiple is defensible and the stock can grind toward the $735 high target; if markets roll over, the same leverage that drives upside would compress both the fee base and the multiple simultaneously, as the July and October air-pockets to the mid-$500s demonstrated.
Bullish
- Elite margins with operating leverage: Q3 2026 gross margin hit 82.94% and operating margin 56.29%, with EBITDA margin at 62.15% ($554.4M on $892.0M revenue). These are top-decile economics for financial data businesses, and margins ticked up sequentially from Q2's 82.71% gross and 56.23% operating, showing the subscription model scales without proportional cost growth.
- Steady low-double-digit revenue compounding: Q3 2026 revenue of $892.0M grew 12.42% YoY from $793.4M, and the sequential cadence ($850.8M Q1, $867.0M Q2, $892.0M Q3) shows consistent, non-lumpy expansion. The Index franchise at $532.6M (~60% of revenue) is a recurring toll on $18 trillion of benchmarked assets, giving high visibility into future fees.
- Strong analyst conviction and target upside: 16 of 17 analysts rate MSCI Buy (consensus 'strong_buy', mean 1.5), with an average target of $684.12 implying +6.7% upside from $641.01 and a high target of $735 implying +14.7%. Consensus 2027 EPS of $31.96 versus the current run-rate supports the forward PE compression to 28.58x from 36.82x trailing.
- Powerful relative strength and momentum: MSCI outperformed SPY by 20.41 percentage points over one month and 18.73 points over three months while the S&P fell 4.99% and 4.91% respectively, confirming idiosyncratic strength rather than beta-driven gains. The stock is up 15.42% in a month and sits at 94.1% of its 52-week range ($501.08–$681.04), a classic acceleration pattern.
Bearish
- Premium valuation leaves no margin for error: At 36.82x trailing PE, 25.93x EV/EBITDA, and 15.29x EV/Sales, MSCI trades well above the typical 15–20x PE and 10–14x EV/EBITDA of diversified financial-data peers. The PEG of 3.48 signals the market is paying heavily for growth, so any deceleration would likely trigger multiple compression.
- Asset-based fees levered to market levels: Roughly 60% of revenue ($532.6M of $892.0M in Q3) comes from the Index franchise, much of it asset-based fees tied to ETF AUM and global equity levels. A market drawdown directly shrinks the fee base, which is why the stock air-pocketed to $550.79 in July and $535.95 in October during volatility.
- Thin liquidity and heavy leverage nuance: The current ratio of 0.899 is below 1.0, cash is only $261.0M, and interest expense of $74.8M gives interest coverage of roughly 6.7x. Negative book value (debt-to-equity -2.39) reflects buyback-driven equity shrinkage, but it means the company depends on uninterrupted cash generation to service debt and fund returns.
- Crowded consensus with no fresh catalysts: The institutional ratings log shows only reiterations — no upgrades or downgrades — for months, and the 26%-of-price spread between the $585 low and $735 high target reveals real dispersion beneath unanimous bullishness. With the average target implying just +6.7% upside, much of the good news appears priced in after the 15.4% one-month rally.
MSCI Technical Analysis
MSCI is in a sustained, choppy uptrend that has reasserted itself decisively in recent weeks. The stock is up 10.44% over the trailing year and 13.40% year to date, and at $641.01 it sits roughly 94.1% of the way through its 52-week range of $501.08 to $681.04 — a positioning that signals momentum leadership but also leaves limited headroom to the prior high, raising the risk of overhead supply near $681. The 180-day price series shows a clear higher-low structure: a May trough near $544.56, a July air-pocket to $550.79, and a September base around $535.95 before the October breakout, confirming buyers have repeatedly defended the mid-$500s.
Short-term momentum is accelerating sharply and diverging positively from the longer-term trend. The stock has gained 15.42% over the past month and 13.82% over three months, versus a 1-year gain of just 10.44%, meaning most of the annual return was earned in the last several weeks — a classic acceleration pattern rather than a decelerating one. Relative strength confirms the move is idiosyncratic, not beta-driven: MSCI outperformed SPY by 20.41 percentage points over one month and 18.73 points over three months while the S&P itself fell 4.99% and 4.91% respectively. The one caveat is the most recent session, a -2.27% pullback from $655.91 to $641.01 on 520,390 shares, which looks like normal profit-taking after the post-earnings spike to $674.30 rather than a trend break.
Key technical levels are well defined. Resistance sits at the 52-week high of $681.04, and a clean breakout above that level would confirm the multi-month base and likely invite momentum and trend-following capital; support clusters at the $600–$620 breakout shelf, with the 52-week low of $501.08 as the ultimate floor. With a beta of 1.192, MSCI is roughly 19% more volatile than the market, so position sizing should account for amplified drawdowns — the stock's max drawdown of -18.07% over the period illustrates that even a high-quality compounder can deliver painful air pockets, and the 2.64 short ratio suggests short interest is modest and not a major squeeze catalyst.
Beta
1.19
1.19x market volatility
Max Drawdown
-18.1%
Largest decline past year
52-Week Range
$501-$681
Price range past year
Annual Return
+13.2%
Cumulative gain past year
| Period | MSCI Return | S&P 500 |
|---|---|---|
| 1m | +16.5% | -2.4% |
| 3m | +15.0% | -2.3% |
| 6m | +17.8% | +2.8% |
| 1y | +13.2% | +11.3% |
| ytd | +17.0% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MSCI Fundamental Analysis
Revenue is growing at a healthy and stable clip. Third-quarter 2026 revenue came in at $892.0 million, up 12.42% year over year from $793.4 million in Q3 2025, and the sequential cadence ($850.8M in Q1, $867.0M in Q2, $892.0M in Q3) shows steady, non-cyclical expansion rather than lumpy spikes. Segment data shows the Index franchise is the engine at $532.6 million (roughly 60% of revenue), with Analytics at $191.0 million, ESG & Climate at $93.7 million, and All Other at $74.7 million — a mix that leans heavily on asset-based index fees, which scale with global equity markets and ETF flows. The consistency of low-double-digit growth supports the thesis that MSCI is a durable compounder, though it also means headline results remain levered to market levels.
Profitability is exceptional and margins are holding at elite levels. Q3 2026 net income was $351.0 million on an 82.94% gross margin and a 54.67% operating margin, with a net margin of 38.36% — figures that are top-decile for financial data and exchange businesses and reflect the operating leverage of a subscription model. The margin trajectory is stable to slightly improving: gross margin moved from 82.71% in Q2 to 82.94% in Q3, and operating margin from 56.23% to 56.29%, while EBITDA of $554.4 million equates to a 62.15% EBITDA margin. One wrinkle is the reported EPS of $4.87 versus a trailing PE-implied figure distorted by a low headline EPS metric (0.027), but the quarterly income statement clearly shows robust diluted EPS of $4.86, confirming genuine earnings power.
Balance sheet and cash flow are strong but carry a leverage nuance. Trailing free cash flow is $1.54 billion, and Q3 operating cash flow of $436.1 million against capex of just $50.7 million produced $385.4 million of quarterly FCF — a capital-light model that funds itself internally. The company returned capital aggressively in Q3 ($552.6 million of buybacks and $147.8 million of dividends) while repaying $335 million of debt, and cash stood at $261.0 million. The negative debt-to-equity (-2.39) and negative book value reflect years of buyback-driven equity shrinkage rather than distress, but the current ratio of 0.899 and interest expense of $74.8 million (interest coverage around 6.7x) mean liquidity is thin and the company relies on steady cash generation to service debt — a manageable but real constraint.
Quarterly Revenue
$892000000.0B
2026-09
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
82.9%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MSCI Overvalued?
Because MSCI is solidly profitable (Q3 net income of $351.0 million, net margin 38.36%), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 36.82x versus a forward PE of 28.58x, and that 22% compression implies the market expects meaningful earnings growth — consistent with consensus 2027 EPS estimates of about $31.96 versus the current run-rate. The PEG ratio of 3.48 and EV/EBITDA of 25.93x confirm the market is paying up for growth, while the PS ratio of 14.12x and price-to-FCF of 27.87x frame a premium quality-compounder valuation rather than a deep-value one.
Peer comparison is constrained because the provided valuation dataset does not include explicit industry-average multiples, so a precise spread cannot be computed; however, the absolute levels are instructive. A 36.8x trailing PE and 25.9x EV/EBITDA sit well above the typical 15–20x PE and 10–14x EV/EBITDA ranges for diversified financial-data and exchange peers, implying a substantial premium. That premium is defensible on quality grounds — an 82.9% gross margin, 54.7% operating margin, and 38.4% net margin are far superior to most financial-services comparables — but it leaves little room for execution error, and the 15.29x EV/Sales multiple underscores how much of the valuation rests on recurring revenue durability.
Historically, MSCI's own valuation band shows the stock is near the cheaper end of its recent range. The trailing PE has compressed from 38.87x at year-end 2025 and 42.94x in Q1 2024 to 36.82x today, while the PS ratio has fallen from 53.82x at Q4 2025 and 64.62x in Q1 2024 to 14.12x — a dramatic de-rating that partly reflects the denominator (revenue and earnings) catching up to the multiple. The current 36.8x PE sits below the 2024 average in the low-40s, suggesting the market is no longer pricing in peak optimism; that is either a value opportunity if growth persists or a warning that the multiple has structurally reset lower.
PE
36.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 28x~47x
vs. Industry Avg
33.3x
Industry PE ~33.3x*
EV/EBITDA
25.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the interplay between leverage and revenue concentration. Roughly 60% of Q3 2026 revenue ($532.6M of $892.0M) comes from the Index franchise, much of it asset-based fees that scale directly with ETF AUM and global equity levels, so a market decline hits the top line immediately. The balance sheet carries a current ratio of just 0.899, only $261.0M of cash, and $74.8M of quarterly interest expense (interest coverage near 6.7x), while negative book value (debt-to-equity -2.39) reflects years of buyback-driven equity shrinkage. Q3 capital returns of $552.6M in buybacks plus $147.8M in dividends exceeded quarterly FCF of $385.4M, meaning the company leans on steady cash generation and debt repayment capacity to sustain its shareholder-return program. Market and competitive risks stem primarily from valuation compression rather than business erosion. At 36.82x trailing PE, 25.93x EV/EBITDA, and 15.29x EV/Sales, MSCI trades at a substantial premium to the 15–20x PE and 10–14x EV/EBITDA typical of diversified financial-data and exchange peers, and its PEG of 3.48 leaves little cushion if growth slows. Beta of 1.192 means the stock amplifies market moves by roughly 19%, and the 26% spread between the $585 low and $735 high analyst targets signals genuine disagreement about whether the premium multiple can hold. The ratings log showing only reiterations — no upgrades or downgrades — over recent months suggests a crowded consensus that is vulnerable to any deceleration in ETF-linked flows or a de-rating toward peer multiples. The worst-case scenario is a synchronized market decline that compresses both the asset-based fee base and the valuation multiple at once. If global equity markets fell sharply, index fee revenue would shrink alongside AUM while investors de-rated the stock toward peer multiples, a double hit that could take shares toward the 52-week low of $501.08 — roughly -21.8% from the current $641.01 — or the analyst low target of $585 (-8.7%). The stock's observed max drawdown of -18.07% over the past 180 days, including air-pockets to $550.79 in July and $535.95 in October, illustrates how quickly such a move can unfold; a realistic adverse case is a -15% to -22% decline, with the $501–$535 zone as the plausible floor absent a fundamental breakdown in the index franchise.
FAQ
The most severe risk is valuation compression: at 36.82x trailing PE, 25.93x EV/EBITDA, and a 3.48 PEG, a slowdown in growth or a shift toward peer multiples could erase a large share of the premium. Second is asset-based fee sensitivity — roughly 60% of Q3 revenue ($532.6M of $892.0M) comes from the Index franchise, much of it tied to ETF AUM and global equity levels, so a market drawdown hits the top line directly, as the July and October air-pockets to the mid-$500s demonstrated. Third is balance-sheet and liquidity nuance: the current ratio is 0.899, cash is only $261.0M, interest expense is $74.8M per quarter (coverage near 6.7x), and Q3 capital returns of $552.6M in buybacks plus $147.8M in dividends exceeded quarterly FCF of $385.4M. Fourth is crowded consensus — only reiterations for months and a 26%-of-price spread between the $585 low and $735 high target mean there is little fresh buying power if flows stall.
The 12-month view is split into three scenarios. The base case (55% probability, $660–$690) assumes revenue growth decelerates modestly to 10–12%, margins hold at or above 56%, and consensus 2027 EPS of $31.96 materializes, keeping the stock near the $684.12 average target. The bull case (25% probability, $700–$735) requires accelerating ETF-linked flows, a breakout above the $681.04 high, and continued buyback execution pushing shares toward the $735 high target. The bear case (20% probability, $501–$585) envisions a global equity drawdown compressing asset-based fees while the multiple de-rates toward peer levels, retesting the $585 analyst low and potentially the $501.08 52-week low. The base case is most likely, and its key assumption is that global equity markets stay range-bound to modestly higher so the fee base remains stable.
MSCI screens as fairly valued to modestly rich rather than cheap. The trailing PE of 36.82x and EV/EBITDA of 25.93x sit well above the typical 15–20x PE and 10–14x EV/EBITDA of diversified financial-data and exchange peers, and the 3.48 PEG shows investors are paying heavily for growth. On the other hand, the forward PE of 28.58x implies roughly 22% earnings growth, consistent with consensus 2027 EPS of $31.96, and the multiple has compressed from 38.87x at year-end 2025 and 42.94x in Q1 2024 — so the stock is near the cheaper end of its own recent band. The market is pricing in durable low-double-digit revenue growth and stable 56%+ operating margins; if those hold, the premium is defensible, but any deceleration would likely trigger a de-rating toward peer levels.
From a risk/reward standpoint MSCI is a good business at a full price: the $684.12 average analyst target implies just +6.7% upside from $641.01, while the $585 low target implies -8.7% downside and the $501.08 52-week low implies -21.8%. The quality case is strong — 12.42% revenue growth, 82.94% gross margin, 56.29% operating margin, and $1.54B trailing FCF — and 16 of 17 analysts rate it Buy with a 'strong_buy' consensus. But the 36.82x trailing PE and 3.48 PEG leave little cushion, and the stock has already rallied 15.42% in a month, so near-term upside is thin relative to the drawdown risk. It is a good buy for long-horizon investors seeking quality compounding, particularly on a pullback toward the $585 analyst low (roughly 28x forward earnings); it is a less attractive entry for short-term traders chasing momentum near the $681.04 high.
MSCI is best suited to long-term holding rather than short-term trading. The business is a durable compounder with recurring, subscription-like revenue, 82.94% gross margins, and $1.54B of trailing FCF, but its 1.192 beta and -18.07% max drawdown mean short-term price action is dominated by market-level swings in asset-based fees rather than company fundamentals. The dividend yield of 1.26% with a 46.3% payout ratio provides modest income but is not the reason to own it; the case rests on low-double-digit revenue growth and buyback-driven EPS expansion (diluted shares fell from 77.3M to 72.3M year over year). A minimum holding period of three to five years is appropriate to let consensus 2027 EPS of $31.96 and beyond compound through the current 28.58x forward multiple, and investors should size positions for amplified drawdowns given the beta.